The stock of Verona Pharma Plc ADR (VRNA) has gone down by -7.66% for the week, with a 28.19% rise in the past month and a -2.08% drop in the past quarter. The volatility ratio for the week is 8.17%, and the volatility levels for the past 30 days are 7.49% for VRNA. The simple moving average for the last 20 days is 14.28% for VRNA stock, with a simple moving average of -2.17% for the last 200 days.
Is It Worth Investing in Verona Pharma Plc ADR (NASDAQ: VRNA) Right Now?
The 36-month beta value for VRNA is also noteworthy at 0.45. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VRNA is 62.41M, and at present, short sellers hold a 9.61% of that float. The average trading volume of VRNA on June 25, 2024 was 724.39K shares.
VRNA) stock’s latest price update
Verona Pharma Plc ADR (NASDAQ: VRNA)’s stock price has decreased by -1.95 compared to its previous closing price of 15.69. However, the company has seen a -7.66% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2024-05-09 that Verona Pharma plc (NASDAQ:VRNA ) Q1 2024 Results Conference Call May 9, 2024 9:00 AM ET Company Participants David Zaccardelli – President, CEO & Executive Director Mark Hahn – Chief Financial Officer Christopher Martin – Chief Commercial Officer Tara Rheault – Chief Development Officer Conference Call Participants Andrew Tsai – Jefferies Tom Shrader – BTIG Ram Selvaraju – H.C. Wainwright Operator Hello, and welcome to Verona Pharma’s First Quarter 2024 Financial Results and Operating Highlights Conference Call.
Analysts’ Opinion of VRNA
Many brokerage firms have already submitted their reports for VRNA stocks, with Jefferies repeating the rating for VRNA by listing it as a “Buy.” The predicted price for VRNA in the upcoming period, according to Jefferies is $38 based on the research report published on May 22, 2023 of the previous year 2023.
Wedbush, on the other hand, stated in their research note that they expect to see VRNA reach a price target of $27. The rating they have provided for VRNA stocks is “Outperform” according to the report published on September 19th, 2022.
Piper Sandler gave a rating of “Overweight” to VRNA, setting the target price at $31 in the report published on August 26th of the previous year.
VRNA Trading at 7.95% from the 50-Day Moving Average
After a stumble in the market that brought VRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.32% of loss for the given period.
Volatility was left at 7.49%, however, over the last 30 days, the volatility rate increased by 8.17%, as shares surge +25.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.25% lower at present.
During the last 5 trading sessions, VRNA fell by -9.51%, which changed the moving average for the period of 200-days by -21.57% in comparison to the 20-day moving average, which settled at $13.61. In addition, Verona Pharma Plc ADR saw -22.62% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRNA starting from Rickard Kathleen A., who sale 36,248 shares at the price of $1.96 back on May 03 ’24. After this action, Rickard Kathleen A. now owns 2,621,552 shares of Verona Pharma Plc ADR, valued at $71,032 using the latest closing price.
Rickard Kathleen A., the Chief Medical Officer of Verona Pharma Plc ADR, sale 36,248 shares at $2.22 during a trade that took place back on Feb 05 ’24, which means that Rickard Kathleen A. is holding 2,731,624 shares at $80,503 based on the most recent closing price.
Stock Fundamentals for VRNA
Current profitability levels for the company are sitting at:
- -75.67 for the present operating margin
- 0.17 for the gross margin
The net margin for Verona Pharma Plc ADR stands at -67.58. The total capital return value is set at -0.26. Equity return is now at value -25.30, with -20.71 for asset returns.
Based on Verona Pharma Plc ADR (VRNA), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.18. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -27.86.
Currently, EBITDA for the company is -67.15 million with net debt to EBITDA at 2.95. When we switch over and look at the enterprise to sales, we see a ratio of 1119.86. The receivables turnover for the company is 0.08for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.40.
Conclusion
In summary, Verona Pharma Plc ADR (VRNA) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
